Editorial comment

In the treatment paradigm for prostate cancer, the pendulum has swung towards increasing use of active surveillance (AS) for lower risk disease, reflected by the most recent guidelines from the American Urological Association.1 These recommendations are supported largely by level-1 evidence from the PIVOT and ProtecT trials, which revealed similar mortality outcomes between observation and primary treatment for patients with clinically localized disease.2,3 In the present study, the authors characterize the management patterns of a unique, sizable cohort of patients with very low, low, or intermediate risk prostate cancer diagnosed in one of several large community practices distributed geographically across multiple states.

Source: Urology - June 22, 2019 Category: Urology & Nephrology Authors: Nirmish Singla, Vitaly Margulis Source Type: research